arrow
M

Masoud Azodi

Department of Obstetrics
H指数:47
被引数:7,978

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study

铂类化疗与卵巢癌肉瘤生存期的关联:一项回顾性两中心队列研究

2025-12-200
PRE
Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case

RUBY试验之外的不良事件:报道一例真实世界子宫内膜癌病例中的免疫治疗相关心肌炎、肌炎和重症肌无力

2025-09-010
OAAI
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
2024-06-220
PRE
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
2024-04-161
PRE
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
2024-04-091
OA
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer ( vol 126 , pg , 1695 , 2022)
2024-03-040
OA
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
2023-09-071
PRE
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
2022-02-1110
OA
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability
CANCER
IF5.1
2021-12-0749
OAAI
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
2021-08-0130
OA
Integrated mutational landscape analysis of uterine leiomyosarcomas
2021-04-0568
OA
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
2020-02-1243
OAAI
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
2020-01-2238
OAAI
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
2020-01-1427
OAAI
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
2019-10-1756
OAAI